A new tumor cell line (SUIT-4) derived from ascites of a patient with carcinoma of the pancreas has been established in tissue culture and in nude mice, and maintained for over 7 years. In tissue culture, the cells grew as a confluent monolayer with piling up of cells in some areas. The population doubling time during the exponential phase of the cell growth was 43.9 h in vitro. Chromosome count ranged from 63 to 68 with a modal number of 67. Subcutaneous injection of cultured cells into the flanks of nude mice resulted in tumor formation with a doubling time of 88.8 h. Histopathologically, xenografts in nude mice were moderately differentiated tubular adenocarcinoma, and the tumor cells showed spontaneous metastasis to the regional lymph nodes in 6 of 21 nude mice and to the lung in 4 of 21. Transmission electron microphotographs confirmed the ductal cell origin of the carcinoma and revealed that the cells had abundant mitochondria and lysosomes. SUIT-4 cells released carcinoembryonic antigen (3.08 × 102 ng/1 × 106 cells/24 h) and carbohydrate antigen 19-9 (4.75 × 104 U/1 × 106 cells/24 h) during exponential cell growth in vitro. Reverse transcriptase-polymerase chain reaction studies revealed that SUIT-4 cells expressed matrix metalloproteinases 1, 3, 7, 10 and 14.

1.
Health and Welfare Statistics Association: Death. J Health Welf Stat 2000;47:48–60.
2.
Saito Y: Investigation of pancreatic carcinoma registration research in Japan. Suizo 1998;13:63–91.
3.
Kobari M, Matsuno M: Stage classification for pancreatic cancer: Its difference between Japan and UICC (in Japanese). Nippon Shokakibyo Gakkai Zasshi 1997;94:1–7.
4.
Iwamura T, Katsuki T, Ide K: Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 1987;78:54–62.
5.
Iwamura T, Katsuki T: Kinetics of carcinoembryonic antigen and carbohydrate antigen 19-9 production in a human pancreatic cancer cell line (SUIT-2). Gastroenterol Jpn 1987;22:640–646.
6.
Iwamura T, Taniguchi S, Kitamura N, Yamanari H, Kojima A, Hidaka K, Setoguchi T, Katsuki T: Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2). J Gastroenterol Hepatol 1992;7:512–519.
7.
Iwamura T, Caffrey TC, Kitamura N, Yamanari H, Setoguchi T, Hollingsworth MA: P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res 1997;57:1206–1212.
8.
Taniguchi S, Iwamura T, Katsuki T: Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis 1992;10:259–266.
9.
Taniguchi S, Iwamura T, Kitamura N, Yamanari H, Kojima A, Hidaka K, Seguchi K, Setoguchi T: Protein-free culture of the human pancreatic cancer cell line, SUIT-2. Hum Cell 1994;7:207–214.
10.
Yamanari H, Suganuma T, Iwamura T, Kitamura N, Taniguchi S, Setoguchi T: Extracellular matrix components regulating glandular differentiation and the formation of basal lamina of a human pancreatic cancer cell line in vitro. Exp Cell Res 1994;211:175–182.
11.
Dobrynin YV: Establishment and characteristics of cell strains from some epithelial tumors of human origin. J Natl Cancer Inst 1963;31:1173–1195.
12.
Iwamura T, Hollingsworth MA: Pancreatic tumors; in Masters JRW, Palsson B (eds): Cancer Cell Lines. New York, Kluwer Academic, 1998, vol 1, part I: Human Cell Culture, pp 107–122.
13.
Kyriazis AP, Kyriazis AA, Scarpelli DG, Fogh J, Rao MS, Lepera R: Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: Morphologic, biologic, and biochemical characteristics. Am J Pathol 1982;106:250–260.
14.
Chen J: Establishment and studies of two human pancreatic carcinoma in vivo lines by transplanting the tumor into nude mice (in Chinese). Zhonghua Bing Li Xue Za Zhi 1989;18:197–200.
15.
Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JW, Bartram CR: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43:1037–1041.
16.
Yasuda D, Iguchi H, Ikeda Y, Nishimura S, Steeg PS, Misawa T, Nawata H, Kono A: Possible association of Nm23 gene expression and Ki-ras point mutations with metastatic potential in human pancreatic cancer-derived cell lines. Int J Oncol 1993;3:641–644.
17.
Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549–554.
18.
Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T: Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 1991;86:1784–1788.
19.
Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G: Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995;62:407–413.
20.
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61–65.
21.
Stetler-Stevenson WG, Krutzsch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264:17374–17378.
22.
Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A, Kossakowska AE: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 1992;66:1188–1194.
23.
Kitamura N, Iwamura T, Taniguchi S, Yamanari H, Kawano K, Hollingsworth MA, Setoguchi T: High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice. Clin Exp Metastasis 2000;18:561–571.
24.
Duivenvoorden WC, Hirte HW, Singh G: Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 1999;17:27–34.
25.
Kaku M, Nishiyama T, Yagawa K, Abe M: Establishment of a carcinoembryonic antigen-producing cell line from human pancreatic carcinoma. Gann 1980;71:596–601.
26.
Morgan RT, Woods LK, Moore GE, Quinn LA, McGavran L, Gordon SG: Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int J Cancer 1980;25:591–598.
27.
Dexter DL, Matook GM, Meitner PA, Bogaars HA, Jolly GA, Turner MD, Calabresi P: Establishment and characterization of two human pancreatic cancer cell lines tumorigenic in athymic mice. Cancer Res 1982;42:2705–2714.
28.
Yamaguchi N, Uozumi G, Ikeuchi H, Morioka H, Machino M, Kawai K: Establishment and characterization of a carcinoembryonic antigen producing cell line derived from human pancreatic exocrine cancer. Gastroenterol Jpn 1983;18:585–592.
29.
Okabe T, Yamaguchi N, Ohsawa N: Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. Cancer 1983;51:662–668.
30.
Kyriazis AP, McCombs WB 3rd, Sandberg AA, Kyriazis AA, Sloane NH, Lepera R: Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res 1983;43:4393–4401.
31.
Kobari M, Hisano H, Matsuno S, Sato T, Kan M, Tachibana T: Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs. Tohoku J Exp Med 1986;150:231–248.
32.
Drucker BJ, Marincola FM, Siao DY, Donlon TA, Bangs CD, Holder WD Jr: A new human pancreatic carcinoma cell line developed for adoptive immunotherapy studies with lymphokine-activated killer cells in nude mice. In Vitro Cell Dev Biol 1988;24:1179–1187.
33.
Ikeda Y, Ezaki M, Hayashi I, Yasuda D, Nakayama K, Kono A: Establishment and characterization of human pancreatic cancer cell lines in tissue culture and in nude mice. Jpn J Cancer Res 1990;81:987–993.
34.
Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, Kelly DR, Schmid SM, Gelder FB, Rado TA, et al: A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA 1990;87:4012–4016.
35.
Kyriazis AA, Kyriazis AP, Sternberg CN, Sloane NH, Loveless JD: Morphological, biological, biochemical, and karyotypic characteristics of human pancreatic ductal adenocarcinoma Capan-2 in tissue culture and the nude mouse. Cancer Res 1986;46:5810–5815.
36.
Fujii Y, Sekiguchi M, Shiroko Y, Shimizu H, Sugawara I, Hasumi K, Eriguchi M, Ikeuchi T, Uchida H: Establishment and characterization of human pancreatic adenocarcinoma cell line SOJ producing carcinoembryonic antigen and carbohydrate antigen 19-9 (in Japanese). Hum Cell 1990;3:31–36.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.